Natera, Inc.
NTRANatera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
3dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
NTRA Earnings Report
EPS Est: $-0.47 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
How NTRA's past catalysts played out
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is Natera, Inc.'s next FDA catalyst?→
Natera, Inc.'s (NTRA) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NTRA biotech catalysts?→
Add NTRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Natera, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.